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There is a current imperative to reveal more precisely the molecular pathways of early onset of systemic autoimmune diseases
(SADs). The investigation of newly diagnosed drug-naive SAD patients might contribute to identify novel disease-specific and
prognostic markers. The multiplex analysis of 30 plasma proteins in 60 newly diagnosed drug-naive SADs, such as RA
(rheumatoid arthritis, n = 31), SLE (systemic lupus erythematosus, n = 19), and SSc (systemic scleroderma, n = 10) patients,
versus healthy controls (HCs, n = 40) was addressed. Thirty plasma cytokines were quantified using the Procarta Plex™ panel.
The higher expression of IL-12p40, IL-10, IL-13, IFN-γ, M-CSF, IL-4, NTproBNP, IL-17A, BMP-9, PYY (3-36), GITRL, MMP-
12, and TNFRSF6 was associated with RA; IL-12p40, M-CSF, IL-4, GITRL, and NTproBNP were higher in SLE; or NTproBNP,
PYY (3-36), and MMP-12 were increased in SSc over HCs, respectively. The cleaved peptide tyrosine tyrosine (PYY 3-36) was
elevated in RA (361:6 ± 47:7 pg/ml) vs. HCs (163:96 ± 14:5 pg/ml, mean ± SEM, ∗∗∗p = 4 × 10−5). The CI (95%) was 268.05-
455.16 pg/ml for RA vs. 135.55-192.37 pg/ml for HCs. The elevated PYY (3-36) level correlated significantly with the increased
IL-4 or GITRL concentration but not with the clinical scores (DAS28, CRP, ESR, RF, aMCV). We are the first to report cleaved
PYY (3-36) as a specific plasma marker of therapy-naive RA. Additionally, the multiplex plasma protein analysis supported a
disease-specific cytokine pattern in RA, SLE, and SSc, respectively.
1. Introduction
Systemic autoimmune rheumatic diseases (SADs) including
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), and systemic sclerosis (SSc) are characterized by an
abnormal immune system response, complement dysregula-
tion, imbalance of cytokines production, and inflammation
[1]. Their etiology, complex pathogenesis, heterogeneous
Hindawi
Mediators of Inflammation
Volume 2021, Article ID 5523582, 9 pages
https://doi.org/10.1155/2021/5523582
presentation, and unpredictable disease course are still not
fully understood [2]. Therefore, the limitation in diagnosing,
classifying, and treating both RA, SLE, and SSc is significant.
Clinical remission is reached in less than half of the patients,
the personalized therapeutic strategy is still lacking, and the
gap between the first symptoms and the diagnosis may often
lead to irreversible pathologic changes [3]. SADs display clin-
ical heterogeneity as presented by variable prognosis, unpre-
dictable susceptibility to rapid progression to structural
damage in joints in RA, and severe extra-articular organ
manifestations in SLE and SSc. In summary, the need for
biomarkers facilitating early diagnosis and profiling those
individuals at the highest risk for a poor outcome has become
essential [4]. Biomarkers of RA [5, 6], SLE [7, 8], or SSc [9,
10] have been recently reviewed elsewhere. Many of the pre-
vious studies have been performed in established or late-stage
disease in SADs. There is a current imperative to reveal more
precisely the molecular pathways of early treatment-naive
SADs [11]. Furthermore, very few studies have reported a
systematic molecular characterization in RA, SLE, and SSc
parallelly, but none in early treatment-naive patients with
SADs. The investigation of newly diagnosed drug-naive
SAD patients might contribute to identify novel disease-
specific and prognostic markers. The parallel investigation
of SADs also could give us the possibility to recognize novel
checkpoints in their pathways and unknown molecular ther-
apeutic targets. Therefore, we aimed to assay the plasma
content of thirty soluble mediators in newly diagnosed
therapy-naive RA, SLE, or SSc patients versus age- and
gender-matched healthy controls.
2. Materials and Methods
2.1. Patient and Public Involvement. Patients were enrolled
during regular visits at the Department of Rheumatology
and Immunology (University of Szeged). Healthy controls
were voluntary staff members of the BRC or University
of Szeged. Subjects were informed about the research by
a physician. Written informed consent was obtained from
all subjects, and our study was reviewed and approved by
an independent ethical committee of the university. Labo-
ratory studies and interpretations were performed on
coded samples lacking personal and diagnostic identifiers.
The study adhered to the tenets of the most recent
revision of the Declaration of Helsinki. Details about the
study design and handling of biological materials were
submitted to the Human Investigation Review Board of
the University of Szeged under the 149/2019-SZTE Project
Identification code.
2.2. Study Cohorts. The multiplex protein analysis of 60
drug-naive SAD patients, RA patients (n = 31, age median
57, 70.9% female (F), Supplementary Table 1); SLE
patients (n = 19, age median 51, 89.4% F, Supplementary
Table 2); SSc patients (n = 10, age median 51, 88.9% F,
Supplementary Table 3), and 40 age- and gender-matched
healthy controls (age median 48.5, 72.5% F) was performed.
We enrolled newly diagnosed drug-naive RA, SLE, and SSc
patients, who had not received antirheumatic treatment,
including nonsteroidal anti-inflammatory drugs (NSAIDs),
disease-modifying antirheumatic drugs (DMARDs), or
glucocorticoids until the time of blood sampling. The RA
patients were diagnosed according to the latest ACR/EULAR
criteria [12] (Supplementary Table 1). The SLE patients who
met the 2012 Systemic Lupus Collaborating Clinics (SLICC)
criteria and in whom active, newly diagnosed SLE was
present were considered eligible [13]. Several clinical and
immunoserological parameters were present at the time of
diagnosis of SLE (Supplementary Table 2). Ten newly
diagnosed patients fulfilling the criteria proposed by the
2013 ACR/EULAR classification criteria for SSc were
enrolled [14]. Two out of ten were further classified as
those with limited cutaneous SSc, and eight out of ten
with diffuse cutaneous scleroderma according to LeRoy
et al. [15] (Supplementary Table 3). Healthy controls were
age and gender matched to the patients, having a negative
history of rheumatic symptoms and negative status upon
detailed physical and laboratory examination. No
comorbidities were detected in patients and controls that
could have influenced our investigation, nor did they take
any medication that could have interfered with the
measurements.
2.3. Measurement of Plasma Proteins.After the withdrawal of
20ml blood into an EDTA vacutainer (Becton Dickinson),
human peripheral blood mononuclear cells and plasma
samples were purified by Leucosep tubes (Greiner Bio-
One, Austria). PBMCs were used for immunophenotyping
in another project. Plasma fractions were stored at -80°C
in aliquots before running the assay. Luminex xMAP tech-
nology was used to determine the protein concentrations of
30 distinct cytokines/chemokines performing Procarta
Plex™ Immunoassay (ThermoFisher Scientific, Waltham,
MA, USA) according to the instructions of the manufac-
turer. The Luminex panel was designed by the authors
quantifying the proteins listed in Supplementary Table 4.
Briefly, all samples were thawed and diluted with sterile
phosphate-buffered saline (PBS) to 1 : 1 and were tested in
a blind fashion and in duplicate. 25μl volume of each
sample, standard, and universal assay buffer was added to
a 96-well plate (provided with the kit) containing 50μl of
capture antibody-coated, fluorescent-coded beads.
Biotinylated detection antibody mixture and streptavidin-
PE were added to the plate after the appropriate
incubation period. After the last washing step, 120μl
reading buffer was added to the wells, and the plate was
incubated for an additional 5 minutes and read on the
Luminex MAGPIX® instrument. Luminex xPonent 4.2
software was used for data acquisition. Five-PL regression
curves were generated to plot the standard curves for all
analytes by the Analyst 5.1 (Merck Millipore, Darmstadt,
Germany) software calculating with bead median
fluorescence intensity values. The panel of the investigated
30 plasma proteins and the range of the detection (in
pg/ml from the lower limit to the upper limit) are
available in the Supplementary Table 4. Data were pooled
from two independent measurements and plotted in
GraphPad Prism.


































































































































Figure 1: The scatter plots of the protein concentrations of plasma proteins (pg/ml) in drug-naive RA (n = 31) patients versus age- and
gender-matched healthy controls (n = 40) with significant differences (one-way ANOVA, ∗p < 0:05; ∗∗p < 0:01, ∗∗∗p < 0:001) measured by
the Luminex MAGPIX technology. The cleaved peptide tyrosine tyrosine PYY (3-36) was detected as being a novel marker of early-onset
therapy-naive rheumatoid arthritis (RA) (∗∗∗p = 4 × 10−5). The arithmetic mean ± SEM are demonstrated for each cytokine (pg/ml) of RA
(n = 31) patients versus age- and gender-matched healthy controls (n = 40). One dot is the average of two technical replicates.
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Table 1: The summary of the significant differences of plasma cytokine concentrations between drug-naive autoimmune patients (RA, SLE,
SSc) and healthy controls (HCs) in a pairwise comparison. The arithmetic means (mean), standard deviation (SD), and the standard error of
the mean (SEM) of the plasma cytokine concentrations were calculated. The pairwise comparison of the concentrations of each cytokine of
patients versus healthy controls (RA vs. HC; SLE vs. HC; SSc vs. HC) was carried out by one-way ANOVA (∗p < 0:05; ∗∗p < 0:01, ∗∗∗p < 0:001
). The 95% confidence intervals (CI, 95%) were calculated between patients and HCs for each cytokine separately. Italic emphasis corresponds
to overlapping patient’s CI with HCs.
Cytokine Cohort Mean (pg/ml) SD SEM One-way ANOVA (p) CI (95%)
IL-12p40
HC 4.18 2.85 0.45
9.7E-05
3.30-5.06
RA 8.90 6.45 1.16 6.63-11.17
IL-10
HC 4.96 4.66 0.74
3.2E-02
3.51-6.40
RA 12.02 19.69 3.54 5.09-18.95
IL-13
HC 7.25 15.53 2.46
9.7E-05
2.43-12.06
RA 41.74 49.74 8.93 24.23-59.25
IFN-γ
HC 23.64 18.35 2.90
1.6E-02
17.96-29.33
RA 98.83 191.03 34.31 31.58-166.07
M-CSF
HC 27.34 34.09 5.39
4.8E-02
16.78-37.91
RA 100.58 227.01 40.77 20.66-180.49
IL-4
HC 31.14 69.44 10.98
1.7E-03
9.62-52.66
RA 121.79 157.07 28.21 66.50-177.09
NTproBNP
HC 39.24 47.07 7.44 24.64-53.82
RA 142.07 194.66 34.96 1.9E-03 73.55-210.59
IL-17A
HC 15.98 26.99 4.27
3.5E-03
7.62-24.34
RA 154.17 288.13 51.75 52.74-255.6
BMP-9
HC 37.78 34.56 5.46
2.9E-02
27.07-48.49
RA 160.67 347.69 62.45 38.27-283.06
PYY
HC 163.96 91.68 14.50
4.0E-05
135.55-192.37
RA 361.60 265.77 47.73 268.05-455.16
GITRL
HC 110.19 100.94 15.96
1.4E-03
78.91-141.47
RA 901.22 1498.96 269.22 373.54-1428.89
MMP-12
HC 154.26 278.20 43.99
7.4E-03
68.05-240.48
RA 833.00 1525.20 273.93 296.09-1369.91
TNFRSF6
HC 209.45 574.09 90.77
3.9E-03
31.54-387.36
RA 1200.63 1998.27 358.90 497.18-1904.07
IL-12p40
HC 4.18 2.85 0.45
5.7E-06
3.29-5.06
SLE 10.86 7.43 1.70 7.52-14.20
M-CSF
HC 27.34 34.09 5.39
6.8E-03
16.77-37.90
SLE 63.06 63.94 14.67 34.31-91.81
IL-4
HC 31.14 69.44 10.98
5.2E-02
9.61-52.65
SLE 70.16 73.03 16.75 37.32-102.99
GITRL
HC 110.19 100.94 15.96
1.3E-02
78.90-141.47
SLE 217.58 222.56 51.06 117.50-317.65
NTproBNP
HC 39.24 47.07 7.44
1.9E-02
24.64-53.82
SLE 315.89 727.91 166.99 1.69-643.19
NTproBNP
HC 39.235 47.07 7.44
3.8E-03
24.64-53.82
SSc 174.206 272.76 86.25 5.15-343.26
PYY HC 163.9605 91.68 14.50 3.1E-02 135.54-192. 37
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2.4. Statistical Analysis. The arithmetic mean (mean), stan-
dard deviation (SD), and the standard error of the mean
(SEM) of the plasma cytokine concentrations were calcu-
lated. The pairwise comparison of the concentrations of each
cytokine of patients versus healthy controls (RA vs. HC; SLE
vs. HC; SSc vs. HC) was carried out by one-way ANOVA
(∗p < 0:05; ∗∗p < 0:01, ∗∗∗p < 0:001). The 95% confidence
intervals (CI, 95%) were calculated between patients and
HCs for each cytokine separately. Calculations were done in
Microsoft Excel.
3. Results and Discussion
The following 30 plasma cytokines in the custom Procarta
Plex™ panel were quantified in the RA, SLE, and SSc
patients and healthy controls (HCs): SDF-1a, GITRL, IL-
1b, IL-2, IL-4, IL-5, IL-33, IL-10, Insulin, PYY (3-36),
CCL22, IL-13, IL-17A, Gal-3, FKN, IFN-γ, GM-CSF, Lep-
tin, MMP-12, NTproBNP, MCP-1, APRIL, TNFRSF6,
BDNF, BMP-9, IL-12p40, BAFF, M-CSF, Survivin, and
CD40-ligand (Supplementary Table 4). These markers
under investigation were selected by the authors based
on preliminary experiments and literature data. Thirteen
cytokines were significantly elevated in RA vs. HCs
(Figure 1); the concentrations of eleven cytokines in RA
patients showed nonoverlapping confidence interval with
HCs (Table 1).
The protein concentrations were the following (RA vs.
HC, mean ± SEM, respectively), IL-12p40: 8:90 ± 1:16 vs.
4:18 ± 0:45pg/ml; IL-13: 41:74 ± 8:93 vs. 7:25 ± 2:46pg/ml;
IFN-γ: 98:83 ± 34:31 vs. 23:64 ± 2:9pg/ml; IL-4: 121:79 ±
28:21 vs. 31:14 ± 10:98pg/ml; NTproBNT: 142:07 ± 34:96
vs. 39:24 ± 7:44pg/ml; IL-17A: 154:17 ± 51:57 vs. 15:98 ±
4:27pg/ml; BMP-9: 160:67 ± 62:45 vs. 37:78 ± 5:46pg/ml;
PYY (3-36): 361:6 ± 47:73 vs. 163:96 ± 14:5pg/ml; GITRL:
901:22 ± 269:22 vs. 110:19 ± 15:96pg/ml; MMP-12: 833:00
± 273:93 vs. 154:26 ± 43:99pg/ml; and TNFRSF6: 1200:63























































Figure 2: The scatter plots of the protein concentrations (pg/ml) of SLE (n = 19) patients versus age- and gender-matched healthy controls
(n = 40) with significant differences (one-way ANOVA, ∗p < 0:05; ∗∗p < 0:01, ∗∗∗p < 0:001). One dot is the average of two technical replicates.
Table 1: Continued.
Cytokine Cohort Mean (pg/ml) SD SEM One-way ANOVA (p) CI (95%)
SSc 232.962 68.12 21.54 190.73-275.18
MMP-12
HC 154.2605 278.20 43.99
2.1E-02
68.04-240.47
SSc 514.748 798.52 252.52 19.82-1009.66
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Five cytokines, IL-12p40, M-CSF, IL-4, GITRL, and
NTproBNP, were significantly elevated in SLE vs. HC
(Figure 2), and only IL-12p40 had nonoverlapping CI with
HC: 10:86 ± 1:7 vs. 4:18 ± 0:45pg/ml (Table 1).
Three cytokines, NTproBNP, PYY (3-36), and MMP-12,
were significantly increased in SSc vs. HC (Figure 3), but all
had overlapping CI (Table 1).
We are the first to report the cleaved peptide tyrosine
tyrosine PYY (3-36) is an early marker of drug-naive RA vs.
HC. The margin of errors (ME) of the CI are 93.55 for PYY
in the RA (n = 31) group and 28.41 for HC (n = 40), the
95% CI falls between 268.05 and 455.16 pg/ml (361.6 pg/ml
mean ± 93:55 ME) for RA, and the 95% CI is between
135.55 and 192.37 pg/ml for HC (163.96 pg/ml mean ±
28:41 ME) (Table 1). Comparing the concentrations
(mean ± SEM) of PYY (3-36) in RA (361:6 ± 47:7pg/ml)
vs. SLE (189:3 ± 27:5pg/ml), it was significantly higher in
RA (∗p = 1:07 × 10−2), and the CI is not overlapping; 95%
CI falls between 268.05 and 455.16 pg/ml for RA and
135.4 and 243.3 pg/ml for SLE. The amount of the PYY
(3-36) had no significant difference (mean ± SEM) between
RA (361:6 ± 47:7pg/ml) vs. SSC (232:9 ± 21:5pg/ml) with
CI for RA (268.05-455.16 pg/ml, 95%) and SSC (190.73-
275.18 pg/ml, 95%). The amount of the PYY (3-36) had
no significant difference (mean ± SEM) between SLE
(189:3 ± 27:5pg/ml) and SSC (232:9 ± 21:5pg/ml) with CI
for SLE (135.4-243.3 pg/ml, 95%) and SSC (190.73-
275.18 pg/ml, 95%). There was no difference in the concen-
trations of the following cytokines in either RA, SLE, or SSc
patients versus HCs: SDF-1a, IL-1b, IL-2, IL-5, IL-33, Insu-
lin, CCL22, Gal-3, FKN, GM-CSF, Leptin, MCP-1, APRIL,
BDNF, BAFF, Survivin, and CD40-ligand, respectively.
Thirteen cytokines showed significantly elevated concen-
trations in the plasma of SAD patients, distinguishing RA
(Figure 1), SLE (Figure 2), or SSc (Figure 3) from HCs,
respectively. Arranging the values in an ascending order of
the concentrations of the plasma cytokines as a prototype
model delineates a characteristic cytokine/chemokine pat-
tern of RA, SLE, and SSc. Therefore, after performing the
assay, we propose a simple diagnostic algorithm fitting the
curves of cytokine concentration values of early drug-naive
SADs patients vs. HCs to diagnose drug-naïve RA, SLE, or
SSc (Figure 4). Based on these data, we propose the
machine-learning automated classification of drug-naïve
RA, SLE, and SSc, which should be further verified in a ded-
icated clinical study.
Better identification of the specific molecular players of
the early stage of SADs may contribute to the recognition
of novel prognostic markers and could facilitate the
pathogenesis-appropriate timing of therapeutic interven-
tions. In summary, we have quantified plasma proteins in
early SAD patients, prior to therapeutic modification of the
disease pathology. A characteristic pattern of soluble media-
tors was revealed distinguishing early diagnosed therapy-
naive RA, SLE, or SSc from HCs. These eleven markers with
nonoverlapping CI (95%) were associated with RA: IL-
12p40, IL-10, IL-13, IFN-γ, M-CSF, IL-4, NTproBNP, IL-
17A, BMP-9, PYY, GITRL, MMP12, and TNFRSF6, and
one marker, IL-12p40, with SLE versus HCs (Table 1). How-
ever, we suggest our Luminex panel for in vitro diagnostics
and the development of a simple algorithm to differentiate
therapy-naive RA, SLE, or SSc based on the profile of protein
concentrations (Figure 4).
There were no significant correlations in PYY (3-36) con-
centration (pg/ml values) compared to CRP, ESR, RF, aMCV,
and DAS28 scores in RA, separately. However, the concen-
tration of two cytokines in the plasma of drug-naive RA
patients, the IL-4 or GITRL concentrations, showed
correlation with bioactive PYY (3-36) level, respectively.


































Figure 3: The scatter plots of the protein concentrations (pg/ml) of SSc (n = 10) patients versus age- and gender-matched healthy controls
(n = 40) with significant differences (one-way ANOVA, ∗p < 0:05; ∗∗p < 0:01, ∗∗∗p < 0:001). One dot is the average of two technical replicates.
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have been thoroughly studied in RA and associated with
disease severity linked to Th17-cell activation or
autoantibody induction, respectively [16, 17]. However,
their association with the increased concentration with PYY
(3-36) needs further mechanistic studies to explain. We
describe here the cleaved peptide tyrosine tyrosine (PYY 3-
36) as a plasma marker of early-onset drug-naive RA. The
1-36 peptide YY (PYY) as a gut hormone has been reported
to be activated by dipeptidyl peptidase-IV (DPP-IV or
CD26) cleavage resulting in PYY (3-36) which binds to Y2
(coded by NPY2R) receptors in the hippocampus reducing
appetite [18, 19]. Chen et al. showed that plasma PYY
concentration was negatively correlated with the increase of
body weight in RA patients followed by etanercept therapy
[20]. The authors have no direct evidence, but the literature
and our data may suggest that the elevated plasma PYY (3-
36) level contributes to the reduced appetite and cachexia
of RA patients. Chen et al. already shed light on PYY as a
link between the gastrointestinal neuroendocrine axis and
the immune system [21]. The possible role of Y2 receptor +
microglia, monocytes/macrophages, granulocytes, and
lymphocytes on the immune homeostasis and regulation of
inflammation has been recently reviewed [22]. Further
research is needed to ascertain the role of PYY (3-36) in
early-onset RA and its possible effect on the innate or
adaptive arm of the immune system and whether it has a
regulatory effect or its increase in the blood is just a
consequence of the pathomechanism of RA.
4. Conclusions
We are the first to report PYY (3-36) as a specific plasma
marker of drug-naive RA. Additionally, the multiplex analy-
sis of 30 plasma proteins supported a disease-specific cyto-
kine pattern in RA, SLE, and SSc, respectively. Based on
these data, we could delineate a prototype model for the
machine-learning automated classification of drug-naive
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Figure 4: The concentrations of plasma cytokines (pg/ml) in the ascending order of (a) RA (n = 31), (b) SLE (n = 19), and (c) SSc (n = 10)
patients versus age- and gender-matched healthy controls (n = 40) measured by the Luminex MAGPIX technology. The cleaved peptide
tyrosine tyrosine PYY (3-36) is a novel marker of early-onset therapy-naive rheumatoid arthritis (RA) (∗∗∗p = 4 × 10−5). The arithmetic
mean ± SEM are demonstrated for each cytokine on a log10 scale in GraphPad Prism software. The connecting lines delineate a




Additional data are in the Supplementary Files, or raw data
can be requested from the corresponding author.
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Supplementary Materials
Supplementary 1. Supplementary Table 1: clinical character-
istics of RA study participants. The median DAS28 disease
activity score was 6.01, and Q1-Q3 interquartiles were 5.4-
6.5. Several clinical and immunoserological parameters were
present at the time of diagnosis of RA including RF: rheuma-
toid factor; MCV: mutated citrullinated vimentin; CRP: C-
reactive protein; ESR: erythrocyte sedimentation rate. Data
are expressed as median and interquartile range (Q1, Q3)
for continuous variables and as number (n) and (%) for cat-
egorical variables. BLD: below the detection limit.
Supplementary 2. Supplementary Table 2: clinical character-
istics of SLE study participants. The median SLEDAI-2K
activity score was 16, and Q1-Q3 interquartiles were 10-21.
Several clinical and immunoserological parameters were
present at the time of diagnosis of SLE including ANA (anti-
nuclear antibodies); anti-DNA antibody; LA (lupus anticoag-
ulant) (activated partial thromboplastin time > 40 s, 8/19);
hemolytic anemia (hematocrit < 0:35, 4/19); nonhemolytic
anemia (hematocrit < 0:35, 4/19); leukopenia (leukocyte
count < 3000/mm3, 8/19); lymphopenia (lymphocyte count
< 1500/mm3, 7/19); and thrombocytopenia (thrombocyte
count < 100000/×106 l, 7/19). Data are expressed as median
and interquartile range (Q1, Q3) for continuous variables
and as number (n) and (%) for categorical variables.
Supplementary 3. Supplementary Table 3: clinical character-
istics of SSc study participants. Several clinical and immuno-
serological parameters were present at the time of diagnosis
of SSc including ANA (antinuclear antibodies); anti-Scl-70,
anti-Scl-70 antibodies; ACA (anticentromere antibodies);
and anti-RNA polymerase III antibodies. Data are expressed
as median and interquartile range (Q1, Q3) for continuous
variables and as number (n) and (%) for categorical variables.
dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc;
skin scoreb: modified Rodnan skin thickness score.
Supplementary 4. Supplementary Table 4: the list of the pro-
teins measured in the plasma of the human subjects enrolled
in the study. The lower range of the detection corresponds to
the threshold of the sensitivity of the assay. The Procarta
Plex™ panel was designed by the authors, and the assay was
loaded on a MAGPIX Luminex instrument.
Supplementary 5. Supplementary Figure 1: the Pearson corre-
lations of the plasma concentrations of IL-4 vs. PYY (3-36) or
GITRL vs. PYY (3-36) in RA patients were analyzed in Micro-
soft Excel. The Pearson correlation coefficients were 0.819 for
IL-4 vs. PYY (3-36) and 0.864 for GITRL vs. PYY (3-36). The t
-statistic (t) was calculated in Microsoft Excel following this
equation≔ðr ∗ SQRT ðn − 2ÞÞ/ðSQRT ð1 − r2ÞÞ, where n is
number of subjects and r is the Pearson coefficient. Then,
the p value was calculated in Microsoft Excel following this
equation: = TDIST ðt, DF, tailsÞ, where DF = n − 2, degree of
freedom. Thepwas1:8 × 10−8 (∗∗∗) for the correlation of IL-4
vs. PYY (3-36) concentrations. Thepwas3:9 × 10−10 (∗∗∗) for
the correlation of GITRL vs. PYY (3-36) concentrations.
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